Furthermore, reduced levels of IL-2(+)CD3(+) and IFN-γ(+)CD3(+) in patients with FSGS were correlated with response to rituximab and were recently suggested as markers of beneficial outcome of the disease, supporting the results from our study (25). The gene discussed is IL2; the disease is focal segmental glomerulosclerosis.